CYP2C19 Double Nickase Plasmid (h): sc-404808-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP2C19 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CYP2C19 Double Nickase Plasmid (h) and CYP2C19 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CYP2C19. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2C19 Double Nickase Plasmid (h) | sc-404808-NIC | 20 µg | $410.00 | |||
CYP2C19 Double Nickase Plasmid (h2) | sc-404808-NIC-2 | 20 µg | $410.00 |
Human CYP2C19 encodes a microsomal cytochrome P450 monooxygenase that catalyzes NADPH-dependent oxidation of diverse xenobiotics and endogenous substrates in the endoplasmic reticulum. As part of Phase I metabolism, CYP2C19 contributes to redox cycling and coupling with cytochrome P450 reductase, shaping downstream conjugation pathways and overall cellular detoxification capacity. Genetic and regulatory variation in CYP2C19 alters metabolic flux and can influence cellular sensitivity to chemical exposures and drug biotransformation phenotypes relevant to pharmacogenomics. In research settings, CYP2C19 is used to interrogate hepatic and extrahepatic metabolic competence, enzyme–substrate specificity, and mechanisms linking xenobiotic metabolism to cellular stress responses.
CYP2C19 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CYP2C19 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CYP2C19. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CYP2C19 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CYP2C19-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.